Sionna Therapeutics, Inc./$SION

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Sionna Therapeutics, Inc.

Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.

Ticker

$SION
Sector
Health
Primary listing
NASDAQ

Employees

41
Headquarters
Waltham, United States
Website
www.sionnatx.com

SION Metrics

BasicAdvanced
$1.3B
-
-$3.79
-
-

Bulls say / Bears say

Sionna reported positive Phase 1 safety, tolerability and pharmacokinetic data for its NBD1 stabilizers SION-719 and SION-451, hitting projected PK benchmarks with no new safety issues, and received IND clearance for SION-719, supporting confidence in the new mechanism (Sionna Therapeutics IR).
With $168 million in cash at year-end 2024 plus $219.2 million in gross IPO proceeds, Sionna expects funding to last through 2028, giving it a multi-year runway to develop its cystic fibrosis pipeline with no immediate dilution risk (GlobeNewswire).
Stifel reaffirmed its Buy rating and $32 price target on Sionna shares following Phase 1 updates, signaling analyst confidence in the stock’s potential after early clinical safety and PK achievements (Investing.com).
Sionna’s net loss widened to $61.7 million in FY 2024 from $47.3 million in 2023, reflecting higher R&D spending that could strain finances if future raises encounter tough market conditions (GlobeNewswire).
Key milestones are still far off, with Phase 2a proof-of-concept data for SION-719 not expected until mid-2026, extending clinical timelines and increasing the risk tied to future results (Sionna Therapeutics IR).
Vertex’s EU approval of its next-generation triple-combination cystic fibrosis therapy Alyftrek in July 2025 further entrenches its dominance, making it harder for Sionna’s NBD1 stabilizers to gain a foothold in the already crowded CFTR modulator market (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SION

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs